Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Matrix Asset Advisors Inc. NY

Matrix Asset Advisors Inc. NY cut its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.2% during the second quarter, Holdings Channel.com reports. The fund owned 126,923 shares of the medical equipment provider’s stock after selling 4,173 shares during the period. Matrix Asset Advisors Inc. NY’s holdings in Zimmer Biomet were worth $11,577,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Zimmer Biomet by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 23,052,925 shares of the medical equipment provider’s stock valued at $2,609,130,000 after acquiring an additional 166,763 shares during the period. Dodge & Cox boosted its holdings in Zimmer Biomet by 2.3% in the 1st quarter. Dodge & Cox now owns 19,564,454 shares of the medical equipment provider’s stock worth $2,214,305,000 after buying an additional 446,018 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in Zimmer Biomet by 236.0% in the 1st quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider’s stock worth $517,039,000 after buying an additional 3,208,596 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Zimmer Biomet by 251.3% in the 1st quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock worth $235,571,000 after buying an additional 1,488,918 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in Zimmer Biomet by 2.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,058,898 shares of the medical equipment provider’s stock worth $233,009,000 after buying an additional 58,060 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on ZBH shares. Rothschild & Co Redburn started coverage on Zimmer Biomet in a report on Thursday, September 18th. They issued a “buy” rating and a $130.00 price objective on the stock. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zimmer Biomet in a report on Wednesday. Rothschild Redb upgraded Zimmer Biomet to a “strong-buy” rating in a report on Thursday, September 18th. UBS Group lifted their price objective on Zimmer Biomet from $91.00 to $96.00 and gave the stock a “sell” rating in a report on Friday, August 8th. Finally, Roth Capital reiterated a “buy” rating on shares of Zimmer Biomet in a report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $112.67.

Zimmer Biomet Trading Down 2.6%

Shares of Zimmer Biomet stock opened at $94.79 on Friday. The stock has a market cap of $18.78 billion, a P/E ratio of 23.06, a P/E/G ratio of 2.18 and a beta of 0.67. The stock’s 50 day simple moving average is $101.31 and its 200-day simple moving average is $98.25. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.22 and a 1-year high of $114.72. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.98 by $0.09. The business had revenue of $2.08 billion for the quarter, compared to analysts’ expectations of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The business’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet’s payout ratio is presently 23.36%.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,500 shares of Zimmer Biomet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $104.15, for a total transaction of $156,225.00. Following the sale, the senior vice president owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. The trade was a 18.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.39% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.